About Us
Phase3.bio places the FDA review team’s deliberative process for drug evaluation into perspective so directors of research at drug development companies better understand the implications for their pending drug approvals. Learn More
Case 01: ODAC Approves New BLINCYTO® (Blinatumomab) Application
Phase3.bio Case Report: FDA Oncologic Drug Advisory Committee March 7, 2018
Our latest case summary covers a pivotal win for Amgen, which was granted accelerated approval to Blincyto (blinatumomab)